Evidence map›Paper›PMID 24457959›Full record

ArticleCell death & disease2014

The fine-tuning of TRAF2-GSTP1-1 interaction: effect of ligand binding and in situ detection of the complex.

A De Luca, G Mei, N Rosato, E Nicolai, L Federici, C Palumbo, A Pastore, M Serra, A M Caccuri

Open access · goldAbstract read
In one paragraph

Article in Cell death & disease, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 42 citations in OpenAlex.

  1. Trial
  2. Structural dynamics and pH-regulated membrane binding of the TRAF2-NC trimer.Protein science : a publication of the Protein Society · 2026
    Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Glutathione-Dependent Pathways in Cancer Cells.International journal of molecular sciences · 2024
    Review
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Review
  16. GlutathioneFrontiers in oncology · 2022
    Article
  17. Article
  18. Glutathione S-Transferases in Cancer.Antioxidants (Basel, Switzerland) · 2021
    Review
  19. Protein Lipoxidation: Basic Concepts and Emerging Roles.Antioxidants (Basel, Switzerland) · 2021
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

A De LucaThe NAST Centre for Nanoscience & Nanotechnology & Innovative Instrumentation, University of Tor Vergata, Rome, Italy.
G MeiDepartment of Experimental Medicine and Surgery, University of Tor Vergata, Rome, Italy.
N RosatoDepartment of Experimental Medicine and Surgery, University of Tor Vergata, Rome, Italy.
E NicolaiDepartment of Experimental Medicine and Surgery, University of Tor Vergata, Rome, Italy.
L FedericiDepartment of Biomedical Sciences, University of Chieti G D'Annunzio, CeSI Center of Excellence on Aging, Chieti, Italy.
C PalumboDepartment of Clinical Sciences and Translational Medicine, University of Tor Vergata, Rome, Italy.
A PastoreLaboratory of Metabolomics and Proteomics, Children's Hospital IRCCS Bambino Gesù, Rome, Italy.
M SerraLaboratory of Experimental Oncology, Istituto Ortopedico Rizzoli IRCCS, Bologna, Italy.
A M Caccuri1] The NAST Centre for Nanoscience & Nanotechnology & Innovative Instrumentation, University of Tor Vergata, Rome, Italy [2] Department of Experimental Medicine and Surgery, University of Tor Vergata, Rome, Italy.
University of Rome Tor Vergata · ITBambino Gesù Children's Hospital · ITIstituto Ortopedico Rizzoli · ITUniversity of Chieti-Pescara · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We provide the first biochemical evidence of a direct interaction between the glutathione transferase P1-1 (GSTP1-1) and the TRAF domain of TNF receptor-associated factor 2 (TRAF2), and describe how ligand binding modulates such an equilibrium. The dissociation constant of the heterocomplex is K(d)=0.3 μM; however the binding affinity strongly decreases when the active site of GSTP1-1 is occupied by the substrate GSH (K(d)≥2.6 μM) or is inactivated by oxidation (Kd=1.7 μM). This indicates that GSTP1-1's TRAF2-binding region involves the GSH-binding site. The GSTP1-1 inhibitor NBDHEX further decreases the complex's binding affinity, as compared with when GSH is the only ligand; this suggests that the hydrophobic portion of the GSTP1-1 active site also contributes to the interaction. We therefore hypothesize that TRAF2 binding inactivates GSTP1-1; however, analysis of the data, using a model taking into account the dimeric nature of GSTP1-1, suggests that GSTP1-1 engages only one subunit in the complex, whereas the second subunit maintains the catalytic activity or binds to other proteins. We also analyzed GSTP1-1's association with TRAF2 at the cellular level. The TRAF2-GSTP1-1 complex was constitutively present in U-2OS cells, but strongly decreased in S, G2 and M phases. Thus the interaction appears regulated in a cell cycle-dependent manner. The variations in the levels of individual proteins seem too limited to explain the complex's drastic decline observed in cells progressing from the G0/G1 to the S-G2-M phases. Moreover, GSH's intracellular content was so high that it always saturated GSTP1-1. Interestingly, the addition of NBDHEX maintains the TRAF2-GSTP1-1 complex at low levels, thus causing a prolonged cell cycle arrest in the G2/M phase. Overall, these findings suggest that a reversible sequestration of TRAF2 into the complex may be crucial for cell cycle progression and that multiple factors are involved in the fine-tuning of this interaction.

Indexed as

Amino Acid MotifsBinding SitesCell CycleCell Line, TumorGlutathioneGlutathione S-Transferase piHumansKineticsLigandsOsteosarcomaProtein BindingTNF Receptor-Associated Factor 2GlutathioneGlutathione S-Transferase piGSTP1 protein, humanLigandsTNF Receptor-Associated Factor 2

Identifiers

PMID24457959
PMCPMC4040697
OpenAlexW2116102307

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.